Journal
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
Volume 67, Issue 11, Pages 1063-1071Publisher
OXFORD UNIV PRESS INC
DOI: 10.1097/NEN.0b013e31818b48db
Keywords
beta-Amyloid; Alzheimer disease; DNA vaccine; Microglia
Categories
Funding
- Health and Labour Sciences Research
- Japan Society for the Promotion of Science
- Tokyo Metropolitan Government
Ask authors/readers for more resources
Immunotherapies markedly reduce beta-amyloid (A beta) burden and reverse behavioral impairment in mouse models of Alzheimer disease. We previously showed that new A beta DNA vaccines reduced A beta deposits in Alzheimer disease model mice without detectable side effects. Although they are effective, the mechanisms of A beta reduction by the DNA vaccines remain to be elucidated. Here, we analyzed vaccinated and control Alzheimer disease model mice from 4 months to 15 months of age to assess which of several proposed mechanisms may underlie the beneficial effects of this vaccination. immunohistochemical analysis revealed that activated microglial numbers increased significantly in the brains of vaccinated mice after DNA vaccination both around A beta plaques and in areas remote from them. Microglia in treated mice phagocytosed A beta debris more frequently than they did in untreated mice. Although microglia had an activated morphological phenotype, they did not produce Significant amounts of tumor necrosis factor. Amyloid plaque immunoreactivity and A beta concentrations in plasma increased slightly in vaccinated mice compared with controls at 9 but not at 15 months of age. Collectively, these data suggest that phagocytosis of A beta deposits by microglia plays a central role in A beta reduction after DNA vaccination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available